{"name":"Dexcom","slug":"dexcom","ticker":"DXCM","exchange":"NASDAQ","domain":"dexcom.com","description":"Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A., and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia; and Athenry, County Galway, Ireland.","hq":"San Diego, CA","founded":0,"employees":"11000","ceo":"Kevin Sayer","sector":"Medical Devices / Diabetes Technology","stockPrice":58.37,"stockChange":-0.2,"stockChangePercent":-0.34,"marketCap":"$22.5B","metrics":{"revenue":4817900032,"revenueGrowth":15,"grossMargin":61.5,"rdSpend":599100000,"netIncome":836300000,"cash":2415200000,"dividendYield":0,"peRatio":25,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Dexcom Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Dexcom reported revenue of $1.4 billion for the fourth quarter and $5.3 billion for the full year 2023.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Dexcom and Novo Nordisk Announce Collaboration to Develop Integrated Continuous Glucose Monitoring and Insulin Delivery Systems","summary":"Dexcom and Novo Nordisk announced a collaboration to develop integrated continuous glucose monitoring and insulin delivery systems.","drugName":"","sentiment":"positive"},{"date":"2023-09-22","type":"regulatory","headline":"Dexcom Receives FDA Clearance for G7 Professional Continuous Glucose Monitoring System","summary":"Dexcom received FDA clearance for the G7 Professional Continuous Glucose Monitoring System.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQUG1oX2RPMG4waTFKUkQyX2ZBY2JjMzFOaWJtNnJmRDVyU1FlV0o2djZaSUlRNmlNZkozY09vdGJlS050aGpUNnQ0VnpJd3RnbVAyUG9HdDVqTE54X0tBaW53ZXZUMWd6QzQzR0xpMTcxVWFhdno3MFpQM3AyWVBGbGRCZmE3WTlrNTg4NmoyaXRJWHRPQkdYT2RDOHREbEQ5OG5EZ21vdkRxMmFSVmoxcXlteWxiSm13VDFXUVdZUXg2UDRUVk5FMkRPQjBCaDdPNE9LeFFjUE85eGRkU2RKZnpyS0pHN0gxc0NzS1hEMHZ6ZmhORHBFTjdLY3hGTTVwd211SEg1U0o2OXVuamNFTlg4U2RCcHc2VW0zTg?oc=5","date":"2026-02-14","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Dexcom (DXCM) and Icon (ICLR) - The Globe and Mail","headline":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Dexcom (DXCM) and Icon (ICLR)","sentiment":"neutral"},{"date":"2026-02-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOUXZfdjAyeEl5MjRRekVWUkw5LU5HU1BnSG1yVVR5LV9ydzloRTVrY19aUXNxWk83LTJieThVcUpqWnltck56NU5ZSWhkMDJkMXhETG51WjdGLTYyUDhZX01ldHB3S1luV1ZGZGVEcldjRDI0U3F0dDNFWlY2Y3FVaktSX3FjU2hUcUFVb3VxV1hTVm5HLUt1UkFCS0RTQ0M2am5vTVNYTEQxU3A4T1hPLU5Hc2pNblAyR1JqbTlpbEFHcWZFV3o5dTJGTS1wbld6aVBDWlRtNUtBM3FHcVIwRWZSWUlkU3p3MWJ2dTVBV00tU3Q0clI3XzAxRms?oc=5","date":"2026-01-07","type":"pipeline","source":"DexCom Investor Relations","summary":"Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer - DexCom Investor Relations","headline":"Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQc1I3Um9aamVkWEpfOEg3emxmdzFIU2hOcWY1b0RtYlh4OEVZSTU5UGM1Wm1iQzNvcVZodXRNbDB6a21aNG5TQ0g0MzdEZnF3SUJoTkplQUZLbWlGUGEzVDNqbG92SzFZNXpSVEd1SjVRbDhnZXZfMXhkaVZORWxnYjF4V2wtaG1GU1U3MUxn?oc=5","date":"2025-12-30","type":"deal","source":"The Motley Fool","summary":"2 Growth Stocks to Buy For 2026 and Beyond - The Motley Fool","headline":"2 Growth Stocks to Buy For 2026 and Beyond","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9Jdmplc0JkVVlORWdmVTNKTUlVRWxRODUtdFNNTFduLUNLdUtDdXd2WkhaaEpKTE4zWDhBV3JRRFJZMnA1S3VmWjRZMXdCUE03a1dPZ2hFOHdtR2JPMTRlbHIzajRUd3Jra2l6OENMOHlfZ2JrLUs2a0hRM3Nadw?oc=5","date":"2025-12-12","type":"pipeline","source":"Drug Delivery Business","summary":"Dexcom to cease G6 CGM production next year, transition fully to G7 - Drug Delivery Business","headline":"Dexcom to cease G6 CGM production next year, transition fully to G7","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNeGJHZG5nN2xjNS1aU3RRUDc4LXVadnU2bGNTQ2pFeGFOOVpRN1NOdVB4THhtSVM2VUh4cEk1U045RE1TNmN5UUh5ZTlCSGVqNERHNEVXanRYTE5rUkRvQUJpamFaS1FYaGhMRkV2bkt1Nkt6d0l0YTFhdG1LLXRxbEExeGZYRTZ3N1RvczF4dkVKS19K?oc=5","date":"2025-11-21","type":"pipeline","source":"Yahoo Finance","summary":"AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo Finance","headline":"AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNUmZxdlFKTDdBbnc1ck13N3pyR3E4NFA0TC03SnZBVDZFeWp2ZUY0Y0NRdFNkMTlEUTA1eWpJeERZeVVTb3l4QXBMTlYwMGRJam9nMlBITmpsdEFNMVpuVWk4V1lUNERqUHI4SUJRb3lRcWItLWpRRW5ZV29xcFBFeXJsaktIQjNwMHRKbE9EWmFYZEFzdjlBY1J2dVktRl8xa09Ycm10YWRSelpJR0k4Z0stRzJIVVBPQTc3NEtMSTlWQQ?oc=5","date":"2025-10-28","type":"earnings","source":"TradingView","summary":"Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption? - TradingView","headline":"Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE45eWQzTjB5aGo2SUo2emV6dTFheGw3bWZFX1IycV9VVXFkNTZqbVlPQjFxRFpvR3Zzdmh6bDc0UXJ0TlNLa1hGd19LbzVaZWRvVTN1MFJEUTNac21iN1lXNnVHdFlkQkhFOFRjcWw3RQ?oc=5","date":"2025-10-14","type":"deal","source":"aol.com","summary":"2 Stocks Down 17% and 21% to Buy Right Now - aol.com","headline":"2 Stocks Down 17% and 21% to Buy Right Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQZ1R6d2dZWnRqVzh5X04xcTNLZzROWkstYnpaOWJlRk9FbF9DQmwzZGFJNzNFbDc3OXZObzNTcjVXMHFROE1YM3h3XzF5U0FCb2lqR01fcFFja0M2MHhmOFFmZG9KOGsyLTVseHhILVlDa3A3LXZ2SU1jQ2pjRXVhc2Z5dXc1LUN0NVY0?oc=5","date":"2025-10-14","type":"deal","source":"The Motley Fool","summary":"2 Stocks Down 17% and 21% to Buy Right Now - The Motley Fool","headline":"2 Stocks Down 17% and 21% to Buy Right Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPRGs4OFdDQy1VQzdfZnJlQW5LUVVqSWt0am9oR2VQVVo3Ynp5eEVjTXk3OV9ZY2tla0xGcHg2QVlmdGVuUTYwYmtLc1dnVlBobHhwUjlqbVUwbzNIdUQwSmtCcjlnQW50a0xMX1JiSmtDVWdSYVA5ZzYzMWJkc2NvbDJrZzJJX01lenV3R2IzQmxBZ2hCQVk5N1g1MGdwV25MQnJBN2RZdnVSVFJhUVRoSE8wUENuNEhLVXgwY1pxd2FFRFJHX0U2dHRqd0ZabXU0aE5pVGhCTmFpNEduYTQtQ0dYVnRTdw?oc=5","date":"2025-06-24","type":"pipeline","source":"reuters.com","summary":"US Health Secretary Kennedy says HHS to launch campaign to encourage wearable devices - reuters.com","headline":"US Health Secretary Kennedy says HHS to launch campaign to encourage wearable devices","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQblhhNXhVN0o1RHEzNkJvdUdHYzZPRV9xRHdpZTZaeTVrZkloVFZnaG9DcWk1aG1mVTQ5VWMtNkluYTMyWHlacV9GY0JTdFkzRHlOVWZ3UlRUNHZWQWZHZmhDdzBiSWpNYVUwTUZhSHpma0NHTi1xWlVadVUxYkl4LXVHV3pERHp0MC1YWGhTMjgydXdudXpib0FsWmJiWkhreUJScjd4WmRHd2llTUxBSWJBTHZjQzFMQjc0UGRTaWoyVGJMRUpkNWVldHJfTEt3ZjVFTGNWNFdnMVNo?oc=5","date":"2025-05-15","type":"earnings","source":"StockStory","summary":"DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook - StockStory","headline":"DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPWTd2MGJMZjFHNUhjWUF3UW5fN2cxR1htako3a3FvcGh3OTJHeTcyYzhmd3M1TWxDLXN4c1JCeFpnb3dRVnNlUmhCd1BuajVYRHRmOEJrMkdTRU4wNWotRVMxX1JHd0l6NHdJN05nWUVpcWRHWktZWkx4R2sxbllxaQ?oc=5","date":"2025-05-01","type":"earnings","source":"Drug Delivery Business","summary":"Analysts are high on Dexcom after Q1 results, $750M repurchase program - Drug Delivery Business","headline":"Analysts are high on Dexcom after Q1 results, $750M repurchase program","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Medtronic","Roche Diagnostics","Abbott Laboratories"],"therapeuticFocus":["Diabetes Technology"],"financials":{"source":"sec_edgar+yahoo","revenue":221000000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":221000000,"period":"2017-12-31"},{"value":184600000,"period":"2017-09-30"},{"value":170600000,"period":"2017-06-30"},{"value":142300000,"period":"2017-03-31"},{"value":171200000,"period":"2016-12-31"}],"grossProfit":2801900000,"grossProfitHistory":[{"period":"2025-12-31","value":2801900000},{"period":"2024-12-31","value":2438200000},{"period":"2023-12-31","value":2288900000},{"period":"2022-12-31","value":1883100000}],"rdSpend":599100000,"rdSpendHistory":[{"period":"2025-12-31","value":599100000},{"period":"2024-12-31","value":552400000},{"period":"2023-12-31","value":505800000},{"period":"2022-12-31","value":484200000}],"sgaSpend":1291000000,"operatingIncome":911800000,"operatingIncomeHistory":[{"period":"2025-12-31","value":911800000},{"period":"2024-12-31","value":600000000},{"period":"2023-12-31","value":597700000},{"period":"2022-12-31","value":391200000}],"netIncome":836300000,"netIncomeHistory":[{"period":"2025-12-31","value":836300000},{"period":"2024-12-31","value":576200000},{"period":"2023-12-31","value":541500000},{"period":"2022-12-31","value":341200000}],"eps":2.09,"epsHistory":[{"period":"2025-12-31","value":2.09},{"period":"2024-12-31","value":1.42},{"period":"2023-12-31","value":1.3},{"period":"2022-12-31","value":0.82}],"cash":917700000,"cashHistory":[{"period":"2025-12-31","value":917700000},{"period":"2024-12-31","value":606100000},{"period":"2023-12-31","value":566300000},{"period":"2022-12-31","value":642300000}],"totalAssets":6339900000,"totalLiabilities":3593900000,"totalDebt":1389700000,"equity":2746000000,"operatingCashflow":1440700000,"operatingCashflowHistory":[{"period":"2025-12-31","value":1440700000},{"period":"2024-12-31","value":989500000},{"period":"2023-12-31","value":748500000},{"period":"2022-12-31","value":669500000}],"capex":-363500000,"capexHistory":[{"period":"2025-12-31","value":-363500000},{"period":"2024-12-31","value":-358800000},{"period":"2023-12-31","value":-236600000},{"period":"2022-12-31","value":-364800000}],"freeCashflow":1077200000,"dividendsPaid":null,"buybacks":-500000000,"employees":11000,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":349700000,"ebit":272600000,"ebitda":339700000,"period":"2026-03-31","revenue":1191900000,"epsBasic":0.52,"netIncome":199500000,"rdExpense":145300000,"epsDiluted":0.51,"grossProfit":750300000,"operatingIncome":255300000},{"sga":321500000,"ebit":344900000,"ebitda":410100000,"period":"2025-12-31","revenue":1259600000,"epsBasic":0.69,"netIncome":267300000,"rdExpense":148200000,"epsDiluted":0.68,"grossProfit":792700000,"operatingIncome":323000000},{"sga":331400000,"ebit":357000000,"ebitda":420600000,"period":"2025-09-30","revenue":1209300000,"epsBasic":0.73,"netIncome":283800000,"rdExpense":157500000,"epsDiluted":0.7,"grossProfit":731400000,"operatingIncome":242500000},{"sga":328000000,"ebit":245800000,"ebitda":308800000,"period":"2025-06-30","revenue":1157100000,"epsBasic":0.46,"netIncome":179800000,"rdExpense":148200000,"epsDiluted":0.45,"grossProfit":688800000,"operatingIncome":212600000},{"sga":310100000,"ebit":159000000,"ebitda":219000000,"period":"2025-03-31","revenue":1036000000,"epsBasic":0.27,"netIncome":105400000,"rdExpense":145200000,"epsDiluted":0.27,"grossProfit":589000000,"operatingIncome":133700000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":58.37,"previousClose":58.57,"fiftyTwoWeekHigh":89.98,"fiftyTwoWeekLow":54.11,"fiftyTwoWeekRange":"54.11 - 89.98","fiftyDayAverage":63.72,"twoHundredDayAverage":68.45,"beta":1.4,"enterpriseValue":21570181120,"forwardPE":19.2,"priceToBook":7.62,"priceToSales":4.67,"enterpriseToRevenue":4.48,"enterpriseToEbitda":16.69,"pegRatio":1.13,"ebitda":1292300032,"ebitdaMargin":26.8,"freeCashflow":1056637504,"operatingCashflow":1782499968,"totalDebt":1384800000,"debtToEquity":46.8,"currentRatio":1.95,"returnOnAssets":9.7,"returnOnEquity":35.6,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":25,"targetMeanPrice":83.28,"targetHighPrice":112,"targetLowPrice":65,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.3,"institutionHeldPercent":99,"sharesOutstanding":385872977,"floatShares":383947471,"sharesShort":18320577,"shortRatio":4.34,"shortPercentOfFloat":4.8,"epsTrailing":2.33,"epsForward":3.05,"revenuePerShare":12.39,"bookValue":7.66,"officers":[{"age":67,"name":"Mr. Kevin Ronald Sayer","title":"Executive Chairman of the Board"},{"age":47,"name":"Mr. Jacob Steven Leach","title":"President, CEO & Director"},{"age":45,"name":"Mr. Jereme M. Sylvain CPA","title":"Executive VP, CFO & Chief Accounting Officer"},{"age":55,"name":"Mr. Michael Jon Brown J.D.","title":"Executive VP & Chief Legal Officer"},{"age":50,"name":"Ms. Sadie M. Stern","title":"Executive VP & Chief Human Resources Officer"},{"age":61,"name":"Mr. Jon  Coleman","title":"Executive VP & Chief Commercial Officer"},{"age":48,"name":"Mr. Girish  Naganathan","title":"Executive VP & CTO"},{"age":null,"name":"Mr. Sean  Christensen","title":"Vice President of Finance and Investor Relations"}],"industry":"Medical Devices","irWebsite":"http://www.dexcom.com/about-dexcom/investor-relations","website":"https://www.dexcom.com","phone":"858 200 0200"}}